Management of chronic anterior uveitis relapses: Efficacy of oral phospholipidic curcumin treatment. Long-term follow-up

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 1201-1206

  Allegri, Pia ^a   Mastromarino, Antonio ^a   Neri, Piergiorgio ^b  

^a Ophthalmological Department of Lavagna Hospital   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Anterior recurrent uveitis; Curcumin; Phosphatidylcholine bound curcumin (Meriva)

Indexed keywords

CURCUMIN; CURCUMIN PHOSPHATIDYLCHOLINE; CYCLOPLEGIC AGENT; IMMUNOSUPPRESSIVE AGENT; MERIVA; MYDRIATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLO; STEROID; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISCOMFORT; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HERPES SIMPLEX; HUMAN; IRIDOCYCLITIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; QUALITY OF LIFE; RECURRENCE RISK; RECURRENT DISEASE; RISK REDUCTION;

EID: 78650689102     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/OPTH.S13271     Document Type: Article

References (42)

1. Bengmark S. Curcumin an atoxic antioxidant and natural NFkappab, cycclooxygenase-2, lipooxygenase and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. J Par Ent Nutr. 2006;30(1):61-62.
2. Bright JJ. Curcumin and autoimmune disease. Adv Exp Med Biol. 2007;595:425-451.
3. Jacob A, Rongqian W, Zhou M, Wang P. Mechanism of the antiinflammatory effect of curcumin: PPAR-γ activation. PPAR Res. 2007:89369.
4. Nonn L, Duong D, Preehl DM. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis. 2007;28: 1188-1196.
5. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix-metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol. 2007;73:1434-1445.
6. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal. 2008;10:511-545.
7. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50:2191-2193.
8. Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokinemediated NF-kappaB Activation pro-inflammatory gene expression by inhibiting inhibitory factor I-kappaB kinase activity. J Immunol. 1999;15:3474-3483.
9. Mohan R, Sivak J, Ashton P, et al. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth-factor-2, including expression of matrix metalloproteinase gelatinase B. J Biolog Chem. 2000;275(14):10405-10412.
10. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "curecumin": from kitchen to clinic. Biochem Pharmacol. 2008;75(4):787-809.
11. Biswas S, Rahman I. Modulation of steroid activity in chronic inflammation: a novel anti-inflammatory role for curcumin. Mol Nutr Food Res. Epub 2008 Mar 10.
12. Yadav VS, Mishra KP, Singh DP, Mehrotra S, Singh VK. Immunomodulatory effects of curcumin. Immunopharmacol Immunotoxicol. 2005;27(3):485-497.
13. Malchiodi-Albedi F, Matteucci A, Bernardo A, Minghetti L. PPAR-γ, microglial cells, and ocular inflammation: new venues for potential therapeutic approaches. PPAR res. 2008:295784.
14. Murata T, He S, Hangai M, et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41(8):2309-2317.
15. Bonne C. PPAR gamma: a novel pharmacological target against retinal and choroidal neovascularization. J Fr Ophtalmol. 2005;28(3):326-330.
16. Siddiqui AM, Cui X, Wu R, et al. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by upregulation of peroxisome proliferator-activated receptor-γ. Critical Care Med. 2006;34(7):1874-1882.
17. Jiang C, Ting T, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
18. Cuomo J, Chernyshev V. Preliminary report-comparative bioavailability of curcuminoids from Meriva® vs 95% curcumin extract. Salt Lake City, UT: Usana Health Sciences, Inc; 2009.
19. Wan YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997;15(12):1867-1876.
20. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007; 4(6):807-818.
21. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemoter Pharmacol. 2007;60:171-177.
22. Lal B, Kapoor AK, Asthana OP, et al. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res. 1999; 13:318-322.
23. Bloch-Michel E, Nussenblatt RB; International Uveitis Study Group Recommendations for the evaluation of intraocular inflammatory diseases. Am J Ophthalmol. 1987;103:234-235.
24. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin. In vitro and in vivo effects on proliferation, apoptosis, signaling and angiogenesis. Cancer. 2005;104(6);1322-1331.
25. Jurenka J. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alt Med Rev. 2009;14(2):141-153.
26. Marczylo TH, Steward WP, Gesher AJ. Rapid analysis of curcumin and curcumin metabolites in rat biomatrices using a novel ultraperformance liquid chromatography method. J Agric Food Chem. 2009;57(3):797-803.
27. Lal B, Kapoor K, Agrawal PK, Asthana OP, Srimal RC. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res. 2000;14(6):443-447.
28. Passos E, Grinstead RL, Khoobehi B. Effectiveness of curcumin, an angiogenesis inhibitor, in experimental choroidal neovascularization in rats. Invest Ophthalmol Vis Sci. 2002;43:E-Abstract 1274.
29. Chen M, Hu D-N, Pan Z, Lu CW, Xue CY, Aass I. Curcumin protects against hyperosmoticity-induced IL-1β elevation in human corneal epithelial cell via MAPK pathways. Exp Eye Res. 2010;90(3):437-443.
30. Kumar PA, Suryanarayana P, Reddy PY, Reddy GB. Modulation of α-crystallin chaperone activity in diabetic rat lens by curcumin. Mol Vision. 2005;11:561-568.
31. Hata M, Sasaki E, Ota M, et al. Allergic contact dermatitis from curcumin (turmeric). Contact Dermatol. 1997;36:107-108.
32. Swierczynska MK, Krecisz B. Occupational skin changes in persons working in contact with food spices. Med Pr. 1998;49:187-190.
33. Sharma RA, Steward WP, Gesher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol. 2007;595:453-470.
34. Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10.
35. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin: a novel strategy for human cancer therapy. J Nanobiotechnology. 2007;5:3.
36. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcuminphospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 2007;330:155-163.
37. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30(2):85-94.
38. Barry J, Fritz M, Brender JR. Determining the effects of lipophillic drugs on membrane structure by solid-state NMR spectroscopy-The case of the antioxidant curcumin. J Am Chem Soc. 2009;131(12):4490-4498.
39. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41(1):40-59.
40. Jeong SJ, Koh W, Lee EO, et al. Antiangiogenic phytochemicals and medical herbs. Phytotherapy Res. 2010 Jun 17 [Epub ahead of print].
41. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med. 1998;4(6);376-383.
42. Kowluru RA, Kanwar M. Effect of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr Metab. 2007;4:8.